Sun, March 16, 2025
[ Sun, Mar 16th ] - techUK
techUK Scale-Up Action Plan
Sat, March 15, 2025
Fri, March 14, 2025
[ Fri, Mar 14th ] - TheStreet
Tax trends and myths
Thu, March 13, 2025
Wed, March 12, 2025
Tue, March 11, 2025
Mon, March 10, 2025

Mallinckrodt and Endo plan merger as they look to recover from opioid litigation


//business-finance.news-articles.net/content/202 .. they-look-to-recover-from-opioid-litigation.html
Published in Business and Finance on by MarketWatch   Print publication without navigation

The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in 2025 and at least $150 million of annual operating synergies by year three.

Mallinckrodt and Endo International, two pharmaceutical companies heavily impacted by litigation related to the opioid crisis, are reportedly in discussions to merge. This potential merger comes as both companies seek to stabilize their financial standings following significant legal settlements. Mallinckrodt, which recently emerged from bankruptcy, has been dealing with the aftermath of a $1.7 billion settlement for its role in the opioid epidemic, while Endo has also faced substantial legal challenges, including a $50 million settlement with Nevada. The merger talks aim at combining resources to better manage their ongoing legal and financial issues, potentially offering a path to recovery and operational continuity amidst the backdrop of the broader pharmaceutical industry's efforts to address the opioid crisis.

Read the Full MarketWatch Article at:
[ https://www.msn.com/en-us/money/general/mallinckrodt-and-endo-plan-merger-as-they-look-to-recover-from-opioid-litigation/ar-AA1AQiaW ]

Publication Contributing Sources